Pay vs Performance Disclosure - USD ($)
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
| Year | Summary Compensation Table Total for PEO(1) | Compensation Actually Paid to PEO(1)(2)(3) | Average Summary Compensation Table Total for Non-PEO NEOs(1) | Average Compensation Actually Paid to Non-PEO NEOs(1)(2)(3) | Value of Initial Fixed $100 Investment based on:(4) | Net Loss(5) (in thousands) | Net Product Sales(6) (in thousands) | |||||||||||||||||||||||||||||||||||||||||||
| Total Shareholder Return | Peer Group Total Shareholder Return | |||||||||||||||||||||||||||||||||||||||||||||||||
| 2025 | $ | 8,457,151 | $ | 24,497,149 | $ | 2,452,691 | $ | 6,034,347 | $ | 140.19 | $ | 124.75 | $ | (25,546) | $ | 410,460 | ||||||||||||||||||||||||||||||||||
| 2024 | $ | 5,204,877 | $ | 10,947,263 | $ | 1,553,201 | $ | 2,746,215 | $ | 122.68 | $ | 118.20 | $ | (321,545) | $ | 226,707 | ||||||||||||||||||||||||||||||||||
| 2023 | $ | 7,574,959 | $ | 885,487 | $ | 2,011,803 | $ | 320,994 | $ | 63.31 | $ | 118.87 | $ | (111,399) | $ | 127,537 | ||||||||||||||||||||||||||||||||||
| 2022 | $ | 5,753,490 | $ | 687,242 | $ | 2,238,982 | $ | 1,118,268 | $ | 148.10 | $ | 113.65 | $ | (278,482) | $ | 200,528 | ||||||||||||||||||||||||||||||||||
| 2021 | $ | 5,739,010 | $ | 6,564,795 | $ | 2,138,273 | $ | 1,957,099 | $ | 218.59 | $ | 126.45 | $ | (180,091) | $ | 210,776 | ||||||||||||||||||||||||||||||||||
2025: Christopher Cline, Peter Heerma, Jula Inrig and William E. Rote.
2024: Christopher Cline, Peter Heerma, Jula Inrig and William E. Rote.
2023: Christopher Cline, Peter Heerma, Elizabeth Reed and William E. Rote.
2022: Laura Clague, Christopher Cline, Peter Heerma, Jula Inrig and William E. Rote.
2021: Laura Clague, Elizabeth Reed, Noah Rosenberg and William E. Rote.
| Year | NEO | Average Summary Compensation Table Total | Deduct: Average of Stock Awards and Option Awards | Add: Average Equity Adjustments | Average Compensation Actually Paid | |||||||||||||||||||||||||||
| 2025 | PEO | $ | 8,457,151 | $ | 6,623,904 | $ | 22,663,902 | $ | 24,497,149 | |||||||||||||||||||||||
| 2025 | non-PEO | $ | 2,452,691 | $ | 1,498,484 | $ | 5,080,140 | $ | 6,034,347 | |||||||||||||||||||||||
The amounts in the Total Equity Adjustments columns in the tables above are derived from the amounts set forth in the following tables:
| Year | NEO | Average Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year | Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards | Average Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year | Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year | Average Fair Value of Last Day of Prior Year of Equity Awards Forfeited During Year | Total Average Equity Adjustments* | |||||||||||||||||||||||||||||||||||||
| 2025 | PEO | $ | 12,142,762 | $ | 8,910,390 | $ | — | $ | 1,610,750 | $ | — | $ | 22,663,902 | |||||||||||||||||||||||||||||||
| 2025 | non-PEO | $ | 2,793,169 | $ | 1,827,374 | $ | — | $ | 459,597 | $ | — | $ | 5,080,140 | |||||||||||||||||||||||||||||||
* The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant.
| Year | NEO | Average Summary Compensation Table Total | Deduct: Average of Stock Awards and Option Awards | Add: Average Equity Adjustments | Average Compensation Actually Paid | |||||||||||||||||||||||||||
| 2025 | PEO | $ | 8,457,151 | $ | 6,623,904 | $ | 22,663,902 | $ | 24,497,149 | |||||||||||||||||||||||
| 2025 | non-PEO | $ | 2,452,691 | $ | 1,498,484 | $ | 5,080,140 | $ | 6,034,347 | |||||||||||||||||||||||
The amounts in the Total Equity Adjustments columns in the tables above are derived from the amounts set forth in the following tables:
| Year | NEO | Average Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year | Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards | Average Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year | Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year | Average Fair Value of Last Day of Prior Year of Equity Awards Forfeited During Year | Total Average Equity Adjustments* | |||||||||||||||||||||||||||||||||||||
| 2025 | PEO | $ | 12,142,762 | $ | 8,910,390 | $ | — | $ | 1,610,750 | $ | — | $ | 22,663,902 | |||||||||||||||||||||||||||||||
| 2025 | non-PEO | $ | 2,793,169 | $ | 1,827,374 | $ | — | $ | 459,597 | $ | — | $ | 5,080,140 | |||||||||||||||||||||||||||||||
* The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant.
Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Company Total Shareholder Return ("TSR")
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and the Company's cumulative TSR over the five most recently completed fiscal years.
Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Net Income
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our net income during the five most recently completed fiscal years. The net product sales shown for years prior to 2023 include revenue from products in the Company’s bile acid portfolio which was divested in August 2023. The Company’s 2023, 2024 and 2025 net product sales do not include any revenue from the bile acid portfolio, which was classified as discontinued operations in 2023.
Description of Relationship Between PEO and Other NEO Compensation Actually Paid and Net Product Sales
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our net product sales during the five most recently completed fiscal years.
Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Company Total Shareholder Return ("TSR")
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and the Company's cumulative TSR over the five most recently completed fiscal years.
In accordance with rules adopted by the Securities and Exchange Commission pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2020, we provide the following disclosure regarding executive compensation for our principal executive officer ("PEO") and Non-PEO NEOs and Company performance for the fiscal years listed below. The Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the years shown.
Required Tabular Disclosure of Pay Versus Performance
The amounts set forth below under the headings “Compensation Actually Paid to PEO” and “Average Compensation Actually Paid to non-PEO NEOs” have been calculated in a manner consistent with Item 402(v) of Regulation S-K. Use of the term “compensation actually paid” is required by the SEC’s rules and as a result of the calculation methodology required by the SEC, such amounts differ from compensation actually received by the individuals and the compensation decisions described in the “Compensation Discussion and Analysis” section above.
The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company's NEOs. These amounts reflect the Summary Compensation Table total with certain adjustments as described in footnote 3 below.The dollar amounts reported represent the amount of net loss reflected in the Company's audited financial statements for the applicable fiscal year.Required Tabular List of Most Important Financial Performance Measures
As is the case with many companies of a similar stage in the biotechnology industry, the Company relies less on financial performance goals as compared to non-financial strategic and operational goals with respect to setting compensation for the NEOs. For the fiscal year ended December 31, 2025, aside from net product sales, which is the company-selected financial measure, the Company did not use other financial performance measures to link Compensation Actually Paid to our NEOs to company performance. For a discussion of the non-financial strategic and operational goals the Company factors into the compensation program for the NEOs, please see the “Compensation Discussion and Analysis” section above.
All of the information provided above under the "Item 402(v) Pay Versus Performance” heading will not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such information by reference.